BAFNA PHARMACEUTICALS LTD Intrinsic Value
BAFNAPH · Healthcare · Current price ₹306.5
Is BAFNA PHARMACEUTICALS LTD undervalued?
DocStoX estimates the fair value of BAFNA PHARMACEUTICALS LTD at ₹84 per share, versus the current market price of ₹307. That puts the stock about -72.5% above our fair-value estimate, which we read as "Avoid". Our confidence in this estimate is low.
How this fair value is calculated
This estimate blends 3 independent methods: Residual income (₹40), Relative P/E (₹183), Graham floor (₹66). We weight each by its reliability and skip any method whose inputs look untrustworthy — "no DCF beats a wrong DCF". This is the same deterministic engine that powers DocStoX stock pages; there is no guesswork or AI-generated number here.
Bear, base and bull scenarios
Our scenarios span ₹40 (bear) to ₹84 (base) to ₹183 (bull). A margin of safety means buying meaningfully below the base case — the wider the gap, the more room for error in the assumptions.
Margin of safety
Value investors demand a margin of safety — a discount to intrinsic value that protects against being wrong. At ₹307 versus an intrinsic value of ₹84, BAFNA PHARMACEUTICALS LTD currently offers -72.5% of negative margin (i.e. a premium).
More on BAFNA PHARMACEUTICALS LTD
DocStoX estimates are generated by a deterministic valuation engine from reported financials — for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.